Literature DB >> 12610741

CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects.

Koichi Ohara1, Shigeru Tanabu, Kazuhisa Ishibashi, Keiko Ikemoto, Kimiko Yoshida, Haruo Shibuya.   

Abstract

OBJECTIVE: The purpose of the present study was to investigate whether plasma fluvoxamine (FV) concentration is associated with CYP2D6*10 allele polymorphisms.
METHODS: Subjects were 46 Japanese patients (21 males) carrying neither *3, *4 nor *5 alleles and treated orally using FV. Venous blood was obtained from each patient for determination of FV concentration/dose (C/D) ratio (plasma concentration of FV divided by daily dose of FV per body weight) and CYP2D6 genotyping.
RESULTS: No significant differences in FV C/D ratio were found between subjects with no (n=13), one (n=18) or two (n=15) *10 alleles.
CONCLUSION: Our results indicate that CYP2D6*10 genotypes do not exert significant effects on FV C/D ratio. As CYP2D6 genotypes differ with ethnic background, further studies should be conducted in different populations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12610741     DOI: 10.1007/s00228-002-0529-3

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

Review 1.  Pharmacogenetics of antidepressant response.

Authors:  Stefano Porcelli; Antonio Drago; Chiara Fabbri; Sara Gibiino; Raffaella Calati; Alessandro Serretti
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

2.  Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis.

Authors:  Benjamin J Grady; Marylyn D Ritchie
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-03-01

3.  Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors.

Authors:  F Gressier; C Verstuyft; P Hardy; L Becquemont; E Corruble
Journal:  J Neural Transm (Vienna)       Date:  2014-07-22       Impact factor: 3.575

4.  Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease.

Authors:  Hideyo Sugahara; Chiharu Maebara; Hisakazu Ohtani; Masanori Handa; Katsumi Ando; Kazunori Mine; Chiharu Kubo; Ichiro Ieiri; Yasufumi Sawada
Journal:  Eur J Clin Pharmacol       Date:  2009-02-19       Impact factor: 2.953

5.  Stable expression of human cytochrome P450 2D6*10 in HepG2 cells.

Authors:  Jian Zhuge; Ying-Nian Yu; Xiao-Dan Wu
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

6.  Pharmacogenetics of antidepressants.

Authors:  Concetta Crisafulli; Chiara Fabbri; Stefano Porcelli; Antonio Drago; Edoardo Spina; Diana De Ronchi; Alessandro Serretti
Journal:  Front Pharmacol       Date:  2011-02-16       Impact factor: 5.810

7.  Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder.

Authors:  Mikhail Sergeevich Zastrozhin; Elena Anatolievna Grishina; Nataliya Petrovna Denisenko; Valentin Yurievich Skryabin; Dmitry Dmitrievich Markov; Ludmila Mikhailovna Savchenko; Evgeny Alekseevich Bryun; Dmitry Alekseevich Sychev
Journal:  Pharmgenomics Pers Med       Date:  2018-06-29

8.  Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors.

Authors: 
Journal:  Genet Med       Date:  2007-12       Impact factor: 8.822

9.  CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression.

Authors:  Kyu-Man Han; Hun Soo Chang; In-Kwang Choi; Byung-Joo Ham; Min-Soo Lee
Journal:  Psychiatry Investig       Date:  2013-09-16       Impact factor: 2.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.